Data Year:

For its 2024 fiscal year, 89BIO INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Rohan Palekar
Chief Executive Officer
Total Compensation $7,619,426 View details Pay Rank By Title In Biotechnology industry #156 View more
Hank Mansbach
Chief Medical Officer
Total Compensation $3,689,407 View details Pay Rank By Title In Biotechnology industry #66 View more
Quoc Le-Nguyen
Chief Technical Operations Officer
Total Compensation $3,665,123 View details Pay Rank By Title In Biotechnology industry #3 View more
Francis Sarena
Chief Operations Officer
Total Compensation $2,691,944 View details Pay Rank By Title In Biotechnology industry #58 View more
Ryan Martins
Chief Financial Officer
Total Compensation $3,415,803 View details Pay Rank By Title In Biotechnology industry #125 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at 89BIO INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. 89BIO INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. 89BIO INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Rohan Palekar
Chief Executive Officer
Total Cash $983,535 Equity $6,619,592 Other $16,299 $7,619,426
Hank Mansbach
Chief Medical Officer
Total Cash $708,812 Equity $2,972,024 Other $8,571 $3,689,407
Quoc Le-Nguyen
Chief Technical Operations Officer
Total Cash $676,800 Equity $2,972,024 Other $16,299 $3,665,123
Francis Sarena
Chief Operations Officer
Total Cash $284,403 Equity $2,400,925 Other $6,616 $2,691,944
Ryan Martins
Chief Financial Officer
Total Cash $636,841 Equity $2,769,278 Other $9,684 $3,415,803
For its 2024 fiscal year, 89BIO INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Rohan Palekar CEO Pay $7,619,426 Median Employee Pay $396,532 CEO Pay Ratio 19:1
For its 2024 fiscal year, 89BIO INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Charles McWherter Total Cash $440,246
Derek DiRocco Total Cash $383,717
Edward Morrow Atkinson, III Total Cash $388,717
Kathleen D. LaPorte Total Cash $398,337
Lota Zoth Total Cash $399,967
Martin Babler Total Cash $489,245
Michael Hayden Total Cash $392,467
Steven Altschuler Total Cash $419,967
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.